Current Report Filing (8-k)
February 19 2021 - 1:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2021
Vaccinex, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38624
|
|
16-1603202
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
1895 Mount Hope Avenue, Rochester, New York
|
|
14620
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (585)
271-2700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per share
|
|
VCNX
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On February 19, 2021, Vaccinex, Inc. (the Company) issued a press release announcing that it had entered into collaboration
agreements with two separate pharmaceutical companies related to ActivMAb®, the Companys antibody discovery and novel viral display platform, for antibody discovery against complex
antigens. The press release is attached to this Form 8-K as Exhibit 99.1.
Item 9.01
|
Financial Statements and Exhibits.
|
The following exhibits are filed herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Vaccinex, Inc.
|
|
|
|
|
Date: February 19, 2021
|
|
|
|
By:
|
|
/s/ Scott E. Royer
|
|
|
|
|
|
|
Scott E. Royer
|
|
|
|
|
|
|
Chief Financial Officer
|
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Sep 2023 to Sep 2024